Health
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J., March 09, 2026--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/ce7f1c52a8ad79646d640571d4b63cf4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yn4N8laKkEzqSje0NzQ2fA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ce7f1c52a8ad79646d640571d4b63cf4","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dmkaGSmuMtcabtdcvvYGAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ce7f1c52a8ad79646d640571d4b63cf4","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 09, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety.","length":650,"tagName":"p"},{"type":"text","content":""We are excited by these results, which underscore Bristol Myers Squibb’s leadership in treating multiple myeloma and our unwavering commitment to patients living with this persistent and challenging disease," said Cristian Massacesi, executive vice president, chief medical officer and head of development at Bristol Myers Squibb. "Importantly, these findings reinforce the value of our CELMoD program and our targeted protein degradation platform, and strengthen our confidence in bringing forward effective, accessible oral treatment options for patients with difficult-to-treat blood cancers and potentially beyond."","length":640,"tagName":"p"},{"type":"text","content":""While t...